Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000722

Drug Information
NameMazindol    
SynonymsSanjorex; 3H-Imidazo(2,1-a)isoindol-5-ol, 2,5-dihydro-5-(4-chlorophenyl)-; SANOREX (TN); Searle Brand of Mazindol; CID4020; Magrilon; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; SAH 42548; Mazindol Medix Brand; Teronak; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; Wyeth Brand of Mazindol; UNII-C56709M5NH; HSDB 3112; D00367; Diestet; Mazindol Searle Brand; Novartis Brand of Mazindol; BRN 0546547; AN 448; D008454; CHEMBL781; DB00579; LS-77865; Mazindol [USAN:BAN:INN]; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; Mazindol (JAN/USP/INN); 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; DEA No. 1605; Solucaps; Sanorex; I06-0844; AC1L1H8E; Mazildene; CHEBI:146385; EINECS 244-857-0; AN448; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-, (+-)-; mazindol; AC-12511; Mazindolum; 3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; MolPort-003-958-662; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; Mazindol Wyeth Brand; Mazindol Novartis Brand; (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; Mazindolum [INN-Latin]; Terenac; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; AN-448; SA 42-548; CCRIS 3152; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-; 22232-71-9; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; S 42548; M2017_SIGMA; Dimagrir; Mazanor; Mazindole; Medix Brand of Mazindol; Teronac    
Trade NameMazanor; Sanorex    
IndicationObesityApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassCentral Nervous System Stimulants    
CAS NumberCAS 22232-71-9
FormularC16H13ClN2O    
PubChem Compound IDCID 4020.    
PubChem Substance IDSID 173110.    
SuperDrug ATC IDA08AA05;    
SuperDrug CAS ID022232719;    
TargetNoradrenergic re-uptakeInhibitor[2]
Ref 1Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000 Oct;13(2):193-9. To Reference
Ref 2Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Apr;13(1):131-48. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543